Trial · NCT00700427
Participant flow65
How many started, completed or left each group, period by period.
1 to 20 of 65
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Study Period 2 (Open-Label Acute Trx) | STARTED | Atomoxetine (Study Period 2) | 2,017 | |
| Study Period 2 (Open-Label Acute Trx) | STARTED | Atomoxetine (Study Period 3A) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | STARTED | Atomoxetine (Study Period 3B) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | STARTED | Placebo (Study Period 3B) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | STARTED | Atomoxetine (Study Period 4) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | Received at Least One Dose of Study Drug | Atomoxetine (Study Period 2) | 2,011 | |
| Study Period 2 (Open-Label Acute Trx) | Received at Least One Dose of Study Drug | Atomoxetine (Study Period 3A) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | Received at Least One Dose of Study Drug | Atomoxetine (Study Period 3B) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | Received at Least One Dose of Study Drug | Placebo (Study Period 3B) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | Received at Least One Dose of Study Drug | Atomoxetine (Study Period 4) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | COMPLETED | Atomoxetine (Study Period 2) | 1,006 | |
| Study Period 2 (Open-Label Acute Trx) | COMPLETED | Atomoxetine (Study Period 3A) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | COMPLETED | Atomoxetine (Study Period 3B) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | COMPLETED | Placebo (Study Period 3B) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | COMPLETED | Atomoxetine (Study Period 4) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | NOT COMPLETED | Atomoxetine (Study Period 2) | 1,011 | |
| Study Period 2 (Open-Label Acute Trx) | NOT COMPLETED | Atomoxetine (Study Period 3A) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | NOT COMPLETED | Atomoxetine (Study Period 3B) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | NOT COMPLETED | Placebo (Study Period 3B) | 0 | |
| Study Period 2 (Open-Label Acute Trx) | NOT COMPLETED | Atomoxetine (Study Period 4) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00700427/flow